Evaluation of the Edaravan Effect on the outcomes ain patients with acute ischemic stroke
Phase 2
- Conditions
- acute ischemic stroke.Cerebral infarction
- Registration Number
- IRCT20210602051472N1
- Lead Sponsor
- Hamedan University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- All
- Target Recruitment
- 60
Inclusion Criteria
Focal neurological symptoms due to cerebrovascular involvement in less than 24 hours
Older age 18 years
Stroke is approved by CT or MRI.
The severity of the stroke should be greater than 4 by the NIHSS criteria and the patient's ability scale before the stroke should be less than 2. It should be noted that it is also injected at intensities higher than 24.
The patient is inclined to enter the study
Exclusion Criteria
Hemorrhagic stroke
Transient stroke
Brain Tumor
Inflammatory diseases and demyelinating brain
History of craniotomy
Previous severe brain trauma
Liver and kidney failure
Pregnancy and lactation
Acute heart attack
Allergy to the drug Adaravan
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Modified Rankin Score (MRS). Timepoint: At the time of discharge and three months after the intervention. Method of measurement: The ability of patients, which is mainly assessed after 90 days by checklist.;NIH Stroke Scale/Score (NIHSS). Timepoint: At the time of discharge and three months after the intervention. Method of measurement: check list.;ESR measurement. Timepoint: At the time of discharge and three months after the intervention. Method of measurement: Blood Samples, Green Blot Method.;CRP Measurement. Timepoint: At the time of discharge and three months after the intervention. Method of measurement: Blood Samples, Immuno-agglutination Assay.
- Secondary Outcome Measures
Name Time Method Side effects of treatment. Timepoint: After discharge and three months after intervention. Method of measurement: checklist.